RNAi silencing in mouse models of neurodegenerative diseases

Research output: Contribution to journalReview articlepeer-review

Abstract

RNA interference (RNAi) has emerged as a potential therapeutic approach for neurodegenerative diseases, particularly those associated with autosomal dominant patterns of inheritance. In proof of concept experiments, several groups have demonstrated efficacy of using viral vectors expressing short hairpin RNA (shRNA) directed against therapeutically relevant genes in mouse models of neurodegenerative diseases, including spinocerebellar ataxia, Amyotrophic Lateral Sclerosis, Huntington's Disease and amyloidosis (a pathological aspect of Alzheimer's Disease). Although viral-based RNAi has limitations that most likely will preclude its usage in humans, a few recent developments underscore the potential of non-viral-based delivery of relevant RNAi as therapeutics for neurodegenerative diseases. Here, I will review the recent literature on effectiveness of RNAi as a therapeutic strategy in mouse models of neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)161-167
Number of pages7
JournalCurrent Drug Delivery
Volume4
Issue number2
DOIs
StatePublished - Apr 2007

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'RNAi silencing in mouse models of neurodegenerative diseases'. Together they form a unique fingerprint.

Cite this